Table 1.
Baseline characteristics of study population.
| All study subjects (n = 154) |
Patients without an LVAD |
Patients with an LVAD |
|
|---|---|---|---|
| Thrombus event (n = 130) | Thrombus event (n = 24) | ||
| Mean age at implant | 55.8 | 55.6 | 56.9 |
| Gender | 33 (21.4) F, 121 (78.6) M | 27 (20.8) F, 103 (79.2) M | 6 (25) F, 18 (75) M |
| Ischemic CM | 85 (55.2) | 71 (54.6) | 14 (58.3) |
| Non-ischemic CM | 69 (44.8) | 59 (45.4) | 10 (41.7) |
| HTN | 65 (42.2) | 54 (41.5} | 11 (45.8) |
| OM | 54 (35.1) | 44 (33.8) | 10 (41.7) |
| Peripheral vascular disease | 13 (8.4) | 10 (7.7) | 3 (12.5) |
| History of tobacco use | 85 (55.2) | 69 (53.1) | 16 (66.7) |
| HMII | 131 (85.1) | 111 (85.4) | 20 (83.3) |
| HVAD | 23 (14.9) | 19 (14.6) | 4 (16.7) |
| Length of pump support (days) | 550 + 475 | 526 + 494 | 682 + 330 |
| BTT | 110 (71.4) | 94 (72.3) | 16 (66.7) |
| DT | 44(28.6) | 36 (27.7) | 8 (33.3) |
| Pump exchange | 14(9.1) | 4(3.1) | 10 (41.7) |
| GI bleed | 40 (26) | 33 (25.4) | 7 (29.2) |
| Driveline infection | 24 (15.6) | 16 (12.3) | 8 (33.3) |
| INTERMACS Profile 1 | 15(9.7) | 15 (11.5) | 0 |
| INTERMACS Profile 2 | 54 (35.1) | 50 (38.5) | 4 (16.7) |
| INTERMACS Profile 3 | 40 (26.0) | 31 (23.8) | 9 (37.5) |
| INTERMACS Profile 4 | 30 (19.5) | 22 (16.9) | 8 (33.3) |
| INTERMACS Profile 5 | 8 (51.9} | 6 (4.6) | 2 (8.3) |
| INTERMACS Profile 6 | 6 (39) | 5 (3.8) | 1 (4.2) |
| INTERMACS Profile 7 | 1(0.6) | 1 (0.6) | 0 |
F—Female; M—Male.